Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Tivozanib (AV-951): Precision VEGFR Inhibitor for Oncolog...

    2026-03-18

    Tivozanib (AV-951): Precision VEGFR Inhibitor for Oncology Research

    Introduction: Unveiling the Power of Tivozanib in Oncology Research

    Targeting the vascular endothelial growth factor receptor (VEGFR) axis is a cornerstone of modern anti-angiogenic therapy. Tivozanib (AV-951) is a next-generation, potent and selective VEGFR tyrosine kinase inhibitor that has rapidly become integral to both preclinical and translational research. With picomolar inhibition of VEGFR-2 (IC50 = 160 pM), minimal off-target activity, and strong synergy in combination therapy—especially with EGFR inhibitors—Tivozanib offers researchers a highly differentiated tool for interrogating and modulating the VEGFR signaling pathway in cancer biology.

    APExBIO supplies rigorously characterized Tivozanib (AV-951), empowering investigators to achieve reproducible and insightful results in studies ranging from renal cell carcinoma (RCC) to innovative anti-angiogenic strategies in solid tumors.

    Principle Overview: Mechanism and Core Applications

    Tivozanib is classified as a pan-VEGFR inhibitor for cancer therapy, targeting VEGFR-1, VEGFR-2, and VEGFR-3 with exceptional selectivity, and displaying limited inhibition of c-KIT and PDGFRβ only at higher, nanomolar concentrations. The quinoline-urea structure underpins Tivozanib’s molecular precision, granting it a favorable safety and efficacy profile in both cell-based and in vivo models. Notably, Tivozanib:

    • Demonstrates superior VEGFR-2 inhibition compared to sunitinib, sorafenib, and pazopanib.
    • Shows robust anti-tumor activity in RCC xenografts and other solid tumor models.
    • Yields a progression-free survival (PFS) of 12.7 months in phase III RCC trials—a benchmark among metastatic RCC treatments.

    As a selective tyrosine kinase inhibitor in oncology research, Tivozanib is particularly valuable for dissecting VEGFR signaling pathway inhibition and for developing combination therapy with EGFR inhibitors, enhancing both cell growth suppression and apoptosis induction in diverse tumor contexts.

    Step-by-Step Workflow: Optimizing Experimental Protocols with Tivozanib

    1. Compound Preparation and Handling

    • Solubility: Dissolve Tivozanib at ≥22.75 mg/mL in DMSO or ≥2.68 mg/mL in ethanol with gentle warming. The compound is insoluble in water.
    • Storage: Store solid Tivozanib at -20°C. Prepare fresh solutions before use; avoid long-term storage of working solutions to prevent loss of activity.

    2. In Vitro Cell-Based Assays

    • Seeding: Seed target cancer cell lines (e.g., RCC, ovarian carcinoma) at appropriate densities in 96-well or 6-well plates, ensuring logarithmic growth phase.
    • Treatment: Add Tivozanib to culture media at a final concentration of 10 μM for 48 hours, as established in literature for robust VEGFR pathway inhibition.
    • Controls: Include DMSO-only controls and, where appropriate, comparator VEGFR inhibitors (e.g., sunitinib, sorafenib) to benchmark potency and selectivity.
    • Combination Therapy: For synergy studies, co-treat with EGFR inhibitors (e.g., erlotinib or gefitinib) at sub-IC50 concentrations, monitoring for enhanced growth inhibition and apoptosis induction.

    3. Readouts and Data Analysis

    • Viability and Cytotoxicity: Assess relative and fractional viability using assays such as CellTiter-Glo, MTT, or flow cytometry-based live/dead staining. Following the methodology detailed in Schwartz, 2022, distinguish between proliferative arrest and cell death for nuanced interpretation of drug response.
    • Phosphorylation Status: Examine VEGFR, PDGFRβ, and c-KIT phosphorylation by Western blot or ELISA, confirming pathway inhibition at the molecular level.
    • Synergy Quantification: Use combination index (CI) analysis (e.g., Chou-Talalay) to determine synergistic effects with EGFR-targeted agents.

    Advanced Applications and Comparative Advantages

    Tivozanib’s exceptional selectivity and potency enable advanced experimental paradigms:

    • Precision Angiogenesis Modeling: By selectively inhibiting VEGFR-1, -2, and -3, Tivozanib allows researchers to dissect specific roles of each receptor in tumor vasculature, outperforming less selective TKIs.
    • Combination Therapy with EGFR Inhibitors: Multiple studies have demonstrated that Tivozanib enhances the anti-tumor efficacy of EGFR-directed therapies, particularly in ovarian and renal cancer cell lines (Tivozanib: Potent VEGFR Inhibitor Optimizing Oncology Research). This synergy is attributed to compounded cell cycle arrest and apoptosis, supporting translational studies of multi-targeted therapies.
    • Benchmarking in Translational Workflows: Compared to sunitinib, sorafenib, and pazopanib, Tivozanib exhibits higher VEGFR-2 selectivity and reduced off-target toxicity, which enables more precise interrogation of VEGFR signaling pathways (Tivozanib: Potent VEGFR Inhibitor for Advanced Oncology Research).
    • In Vivo Xenograft Models: In RCC and solid tumor xenograft studies, Tivozanib has demonstrated superior anti-angiogenic and anti-tumor activity, translating in the clinic to a PFS of 12.7 months—a leading outcome for metastatic RCC (Tivozanib: Mechanistic Precision and Strategic Opportunities).

    These features make Tivozanib an ideal pan-VEGFR inhibitor for cancer therapy, especially when advanced, data-driven approaches are essential for drug development pipelines.

    Troubleshooting and Optimization Tips

    • Solubility Challenges: If Tivozanib does not dissolve fully in DMSO or ethanol, gently warm the solution (≤37°C) and vortex thoroughly. Avoid water as a solvent due to insolubility.
    • Compound Stability: Use freshly prepared solutions. Prolonged storage at room temperature or repeated freeze-thaw cycles can degrade compound potency.
    • Cell Line Sensitivity: Confirm VEGFR expression levels in target cells—low-VEGFR-expressing lines may require higher concentrations or extended exposure for observable effects.
    • Assay Readout Selection: Following best practices from Schwartz, 2022, differentiate between cytostatic and cytotoxic effects by combining proliferation assays (e.g., EdU, BrdU) with cell death markers (e.g., Annexin V/PI).
    • Synergy Validation: When combining with EGFR inhibitors, perform dose-matrix experiments to map interaction landscapes and avoid false-negative or -positive synergy calls.
    • Batch-to-Batch Reproducibility: Source Tivozanib from a trusted supplier like APExBIO to ensure consistent quality and activity between experiments.

    Future Outlook: Tivozanib’s Expanding Role in Translational Oncology

    With the ever-growing complexity of cancer research and the shift towards multifaceted, systems-level evaluation of drug responses, Tivozanib is uniquely positioned to drive innovation. Its pan-VEGFR inhibition profile not only facilitates sophisticated angiogenesis models but also enables integration into next-generation combination regimens.

    Emerging directions include:

    • High-Content Screening: Pairing Tivozanib with automated imaging and multiplexed assays for deeper phenotypic profiling of anti-angiogenic responses.
    • Organoid and Co-culture Systems: Leveraging the selectivity of Tivozanib to study tumor–microenvironment interactions, particularly in patient-derived organoids and immune cell co-cultures (Tivozanib: Transforming In Vitro VEGFR Inhibitor Assays).
    • Personalized Oncology: Incorporating Tivozanib into biomarker-driven studies to optimize patient selection and therapeutic outcomes in RCC and beyond.

    As advanced in vitro methods are refined, as described by Schwartz (2022), the ability to parse cytostatic from cytotoxic effects will be critical for accurate drug evaluation and pipeline advancement. Tivozanib’s molecular precision and favorable toxicity profile make it a foundational component for such next-generation oncology studies.

    Conclusion

    In summary, Tivozanib (AV-951) is redefining the standard for VEGFR signaling pathway inhibition in oncology research. Its unparalleled potency, selectivity, and versatility support a broad spectrum of experimental designs, from single-agent anti-angiogenic therapy to cutting-edge combination protocols. Sourced from APExBIO, Tivozanib ensures reproducibility, enabling researchers to unlock new insights and accelerate the development of effective cancer therapies.